---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-22-000537"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:17:51.246811+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q3 revenue up 28.5% to $7.8M; raises FY2022 guidance to $27.5-28.0M

## Summary
- Net sales $7.76M (+28.5% YoY); domestic core +16.2%, international core +46.8%, novel therapies +251.9%.
- GAAP net loss $1.2M ($0.03 diluted EPS) vs $1.1M loss ($0.02) in Q3 2021; gross margin 55.7% vs 57.9%.
- Full-year 2022 revenue guidance raised to $27.5-28.0M (from $27.0-27.5M); opex guidance lowered to $26.5-27.0M.
- Cash $16.4M; management confirms year-end cash minimum of $16.0M.
- Novel therapies pipeline: four new Phase II trials, one drug progressed to Phase III.

## SEC filing metadata
- accession: 0001161697-22-000537
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/0001161697-22-000537-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-22-000537
- JSON: https://secwatch.observer/filing/0001161697-22-000537.json
- Plain text: https://secwatch.observer/filing/0001161697-22-000537.txt

## Key facts
- Earnings Releases
  KORU Medical Systems, Inc. reported full year 2022 results: revenue $27.5 to $28.0 million. Guidance raised.
  - Period: full year 2022
  - Revenue: $27.5 to $28.0 million
  - Guidance: raised
  - Result: guidance update
  source text: KORU Medical now expects full year 2022 revenue to be in the range of $27.5 to $28.0 million (previously $27.0 to $27.5 million).
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/0001161697-22-000537-index.htm
- Earnings Releases
  KORU Medical Systems, Inc. reported the third quarter ended September 30, 2022 results: revenue $7,760,398, net income $1.2 million, EPS $(0.03) per diluted share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $7,760,398
  - Net income: $1.2 million
  - EPS: $(0.03) per diluted share
  - Result: reported results
  source text: $ % Net Sales Domestic Core $ 5,900,042 $ 5,076,294 $ 823,748 $ 16.2% International Core 1,096,746 747,281 349,465 46.8% Novel Therapies 763,610 216,969 546,641 251.9% Total $ 7,760,398 $ 6,040,544 $ 1,719,854 $ 28.5% Total net sales increased $1.7 million, or 28.5%, for the three months ended September 30, 2022, as compared with the same period last year as we
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169722000537/0001161697-22-000537-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.